Literature DB >> 7023895

Combination use of nonsteroidal antiinflammatory drugs.

D R Miller.   

Abstract

Polypharmacy with nonsteroidal antiinflammatory drugs (NSAIDs) is widely practiced despite being condemned by many rheumatologist. Combination use of aspirin with other NSAIDs might be discouraged for three well-documented reasons. First, aspirin reduces the blood levels of many NSAIDs. Second, multiple drugs are antagonistic or at least less than additive in animal models of inflammation. Third, there is no good clinical data to suggest that combination use of NSAIDs is beneficial. Unless new studies become available, NSAIDs should be used one at a time, with supplementary analgesics added on a prn basis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023895     DOI: 10.1177/106002808101500101

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  6 in total

Review 1.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Pharmacokinetic interaction between indomethacin and diflunisal.

Authors:  A Van Hecken; R Verbesselt; T B Tjandra-Maga; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Interaction between flurbiprofen and indomethacin in rheumatoid arthritis.

Authors:  S R Rudge; J K Lloyd-Jones; I D Hind
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.